Keyphrases
Adverse Events
100%
Management Guidelines
100%
Dermatological Adverse Effects
100%
Prevention Guidelines
100%
Fibroblast Growth Factor Receptor Inhibitor
100%
Fibroblast Growth Factor Receptor 1 (FGFR1)
60%
Bladder Cancer
40%
Effective Management
40%
Cholangiocarcinoma
40%
Effective Treatment
20%
Early Intervention
20%
Cell Proliferation
20%
Cell Membrane
20%
Tyrosine Kinase
20%
Cell Differentiation
20%
Safety Profile
20%
Aberrations
20%
Moderate to Severe
20%
Biological Function
20%
Cell Survival
20%
Quality of Life
20%
Solid Tumors
20%
Oncologists
20%
Patient Well-being
20%
Treatment Strategy
20%
Treatment Emergent
20%
Clinical Benefit
20%
Enhanced Awareness
20%
Intervention Management
20%
Treatment Adherence
20%
Clinical Safety
20%
Growth Factor Receptor Tyrosine Kinase
20%
Management Plan
20%
Premature Discontinuation
20%
Implications for Practice
20%
Stomatitis
20%
Erdafitinib
20%
Skin Effect
20%
Survival Migration
20%
Pemigatinib
20%
Calciphylaxis
20%
Derazantinib
20%
Infigratinib
20%
Futibatinib
20%
Class Effect
20%
Onycholysis
20%
Medicine and Dentistry
Adverse Event
100%
Dermatological Agent
100%
Fibroblast Growth Factor Receptor
100%
Protein Tyrosine Kinase
25%
Quality of Life
25%
Awareness
25%
Bladder Cancer
25%
Cholangiocarcinoma
25%
Nail
25%
Cell Survival
12%
Cell Proliferation
12%
Cell Differentiation
12%
Patient Compliance
12%
Solid Malignant Neoplasm
12%
Cell Membrane
12%
Prematurity
12%
Oncologist
12%
Early Intervention
12%
Biological Functions
12%
Stomatitis
12%
Calciphylaxis
12%
Onycholysis
12%
Pemigatinib
12%
Derazantinib
12%
Erdafitinib
12%
Infigratinib
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Fibroblast Growth Factor Receptor
100%
Dermatological Agent
100%
Protein Tyrosine Kinase
25%
Bladder Cancer
25%
Bile Duct Carcinoma
25%
Prematurity
12%
Solid Malignant Neoplasm
12%
Syndrome
12%
Stomatitis
12%
Erdafitinib
12%
Calcinosis
12%
Infigratinib
12%
Derazantinib
12%
Onycholysis
12%
Pemigatinib
12%